Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gross Margin for 5 consecutive years, with 89.36% as the latest value for Q1 2025.

  • Quarterly Gross Margin rose 154.0% to 89.36% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 89.36% through Dec 2025, up 100.0% year-over-year, with the annual reading at 89.36% for FY2025, 100.0% up from the prior year.
  • Gross Margin for Q1 2025 was 89.36% at Whitehawk Therapeutics, roughly flat from 89.09% in the prior quarter.
  • The five-year high for Gross Margin was 100.0% in Q4 2021, with the low at 85.35% in Q4 2023.
  • Average Gross Margin over 5 years is 90.05%, with a median of 89.23% recorded in 2024.
  • The sharpest move saw Gross Margin tumbled -1041bps in 2023, then skyrocketed 374bps in 2024.
  • Over 5 years, Gross Margin stood at 100.0% in 2021, then fell by -4bps to 95.75% in 2022, then dropped by -11bps to 85.35% in 2023, then grew by 4bps to 89.09% in 2024, then grew by 0bps to 89.36% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 89.36%, 89.09%, and 88.85% for Q1 2025, Q4 2024, and Q3 2024 respectively.